Replies to post #384235 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Elite's Monster Unique second generation IR ADF is 90% cheaper to produce compared to ADFs containing Naltrexone. It can also be used with CNS stimulants to make them abuse deterrent.
The holy grail of IR ADFs trials resume in 2022
Making others obsolete.

Hammer locking the IR ADF market in 2022

Patent Pending

Quote Nasrat:

“I am extremely excited about this formulation because it is also a platform that applies to all the IRs and its about 10% of the cost. So we're extremely excited about this, but it's still early, in the next few months once Dr. Smith files a patent and we do a few more trials, we’ll update everyone more about it. “



ELTP

[jour_trader]

It’s a revised SequestOx. Even being 90% cheaper than incl naltrexone the question is whether it is still competitive with extremely cheap generics? That’s the issue.